Key facts
- AVECTAS’s last known valuation is $71.5M (Jun 2025).
- It has raised $82.7M; the latest was Later Stage VC ($21.3M) in Jun 2025.
- Notable investors include Adapt Pharma, David Brabazon, Horizon 2020, Seamus Mulligan.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for AVECTAS
- ·The full record, as it builds
Funding rounds
No funding rounds for AVECTAS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AVECTAS
Developer of a cell engineering platform intended to enable the ex vivo manufacture of gene-modified cell therapy products. The company's technology permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality, enabling drug developers to develop potent engineered cell therapies at therapeutic volumes with minimal cell disruption.
- Sector
- Healthcare
- HQ
- Ireland
- Founded
- 2011
- Employees
- 37
- Website
- avectas.com/
- Ownership
- Privately Held (backing)
AVECTAS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AVECTAS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AVECTAS in its N-PORT filings yet. We sweep new filings monthly.